New and Novel Therapies for Gynecologic Cancers

Debra L. Richardson

doi:10.1016/j.soncn.2019.02.009

New and Novel Therapies for Gynecologic Cancers

Debra L. Richardson

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

Original language	English (US)
Pages (from-to)	217-219
Number of pages	3
Journal	Seminars in Oncology Nursing
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/j.soncn.2019.02.009
State	Published - Apr 2019
Externally published	Yes

Keywords

bevacizumab
cervical cancer
endometrial cancer
ovarian cancer
parp inhibitors
pembrolizumab

ASJC Scopus subject areas

Oncology(nursing)

Access to Document

10.1016/j.soncn.2019.02.009

Cite this

@article{474f5c7e57c5422fabc28edfd0fe2c53,

title = "New and Novel Therapies for Gynecologic Cancers",

abstract = "Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.",

keywords = "bevacizumab, cervical cancer, endometrial cancer, ovarian cancer, parp inhibitors, pembrolizumab",

author = "Richardson, {Debra L.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.soncn.2019.02.009",

language = "English (US)",

volume = "35",

pages = "217--219",

journal = "Seminars in Oncology Nursing",

issn = "0749-2081",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - New and Novel Therapies for Gynecologic Cancers

AU - Richardson, Debra L.

PY - 2019/4

Y1 - 2019/4

N2 - Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

AB - Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

KW - bevacizumab

KW - cervical cancer

KW - endometrial cancer

KW - ovarian cancer

KW - parp inhibitors

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85062599911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062599911&partnerID=8YFLogxK

U2 - 10.1016/j.soncn.2019.02.009

DO - 10.1016/j.soncn.2019.02.009

M3 - Review article

C2 - 30876683

AN - SCOPUS:85062599911

SN - 0749-2081

VL - 35

SP - 217

EP - 219

JO - Seminars in Oncology Nursing

JF - Seminars in Oncology Nursing

IS - 2

ER -

New and Novel Therapies for Gynecologic Cancers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this